Sinopharm Group Co (SHTDY)
OTHER OTC:SHTDY
Top Page
Sinopharm Group Co
(OTC:SHTDY)
Select Model
Select Model
Rating:69Neutral
Price Target:
$14.50
▲(10.43% Upside)
Action:ReiteratedDate:11/12/25
SHTDY's overall score of 69 reflects a balanced but cautious outlook, driven primarily by moderate financial performance (score 60) with concerns over revenue decline and cash flow volatility. Strong technical momentum (score 85) supports a bullish price trend, while an attractive valuation (score 80) with a low P/E and solid dividend yield adds to the positive outlook. Financial challenges remain the key risk to monitor.
Positive Factors
Strong Cash Generation
Sinopharm's ability to generate cash from operations indicates strong operational efficiency, supporting long-term financial stability and investment capacity.
Negative Factors
Decline in Revenue Growth
A decline in revenue growth may signal challenges in market expansion or competitive pressures, potentially affecting long-term growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Cash Generation
Sinopharm's ability to generate cash from operations indicates strong operational efficiency, supporting long-term financial stability and investment capacity.
Read all positive factors
Sinopharm Group Co (SHTDY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.33B
Dividend Yield3.75%
Average Volume (3M)1.38K
Price to Earnings (P/E)7.8
Beta (1Y)0.30
Revenue Growth-2.32%
EPS Growth-21.16%
CountryUS
Employees108,217
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.83
Shares Outstanding268,362,150
10 Day Avg. Volume773
30 Day Avg. Volume1,375
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)0.78
Price to Sales (P/S)0.11
P/FCF Ratio6.45
Enterprise Value/Market Cap12.53
Enterprise Value/Revenue0.18
Enterprise Value/Gross Profit2.42
Enterprise Value/Ebitda5.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sinopharm Group Co Business Overview & Revenue Model
Company Description
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutic...
How the Company Makes Money
Sinopharm Group generates revenue through multiple key streams, primarily from the wholesale and retail distribution of pharmaceutical products and medical devices. The company operates an extensive network of pharmacies and hospitals, which facil...
Sinopharm Group Co Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
60
Neutral
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 575.82B | 584.51B | 596.57B | 552.15B | 521.05B | 456.41B |
| Gross Profit | 43.09B | 44.26B | 48.51B | 47.43B | 44.05B | 40.32B |
| EBITDA | 20.58B | 20.17B | 26.90B | 26.25B | 24.68B | 22.62B |
| Net Income | 6.80B | 7.05B | 9.05B | 8.53B | 7.76B | 7.19B |
Balance Sheet | ||||||
| Total Assets | 420.17B | 392.83B | 383.39B | 364.78B | 335.41B | 311.24B |
| Cash, Cash Equivalents and Short-Term Investments | 47.16B | 54.31B | 63.81B | 55.22B | 43.54B | 50.22B |
| Total Debt | 93.29B | 76.39B | 73.78B | 69.59B | 68.37B | 68.53B |
| Total Liabilities | 290.70B | 266.14B | 263.08B | 254.71B | 235.76B | 221.29B |
| Stockholders Equity | 80.38B | 78.88B | 74.58B | 68.07B | 61.89B | 56.36B |
Cash Flow | ||||||
| Free Cash Flow | 16.32B | 9.58B | 14.84B | 18.55B | 7.05B | 9.07B |
| Operating Cash Flow | 18.43B | 11.55B | 17.17B | 20.96B | 9.31B | 11.15B |
| Investing Cash Flow | -3.24B | -3.75B | -944.53M | -3.59B | -1.27B | -2.20B |
| Financing Cash Flow | -23.26B | -17.29B | -7.64B | -5.69B | -14.69B | 2.03B |
Sinopharm Group Co Technical Analysis
Positive
13.13
Price Trends
13.40
Negative
13.21
Positive
12.64
Positive
Market Momentum
-0.10
Negative
53.31
Neutral
70.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SHTDY, the sentiment is Positive. The current price of 13.13 is below the 20-day moving average (MA) of 13.20, below the 50-day MA of 13.40, and above the 200-day MA of 12.64, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 53.31 is Neutral, neither overbought nor oversold. The STOCH value of 70.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SHTDY.
Sinopharm Group Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $8.33B | 7.77 | 8.62% | 3.75% | -2.32% | -21.16% | |
69 Neutral | $2.48B | 15.81 | 11.29% | ― | -0.02% | -1.87% | |
68 Neutral | $108.31B | 21.30 | -245.27% | 0.37% | 17.23% | 66.17% | |
65 Neutral | $50.37B | 25.74 | -58.93% | 0.98% | 4.37% | 28.48% | |
65 Neutral | $8.48B | 23.11 | 11.92% | ― | 3.51% | 29.65% | |
64 Neutral | $63.18B | 29.30 | 101.43% | 0.66% | 9.31% | 5.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SHTDY
Sinopharm Group Co
13.35
2.67
24.96%
COR
Cencora
324.80
52.19
19.15%
CAH
Cardinal Health
214.05
89.77
72.23%
HSIC
Henry Schein
73.94
9.63
14.97%
MCK
McKesson
884.28
224.92
34.11%
PBH
Prestige Consumer Healthcare
52.48
-28.98
-35.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.